Work

FKBP9 enhances IGF2BP1-mediated m6A recognition to promote hepatocellular carcinoma progression

Year: 2025

Type: article

Abstract: Background & Aims: A modification during the development of hepatocellular carcinoma (HCC). Methods: analysis. Immunoprecipitation, mass spectrometry, methylated RNA immunoprecipitation sequencing, and RNA sequencing were performed to elucidate underlying mechanisms. Results: <0.05). Conclusions: FKBP9 promotes HCC progression by facilitating IGF2BP1 recognition of m6A-modified transcripts, thereby stabilizing MYC and PDGFB. The FKBP9-IGF2BP1 axis represents a potential therapeutic target in HCC. Impact and implications: . These findings provide new insights into the molecular mechanisms driving hepatocellular carcinoma and identify potential therapeutic opportunities for patients with poor prognosis linked to high FKBP9 expression. The FKBP9-IGF2BP1 axis may serve as both a biomarker and a therapeutic target to guide the development of new treatment strategies. Further studies are warranted to validate these results in larger patient cohorts and to assess the clinical feasibility of targeting this pathway.

Source: JHEP Reports

DOI: 10.1016/j.jhepr.2025.101584